NCT07018050

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

A Multicenter, Open-Label Phase II Study to Evaluate QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	QLS32015	QLS32015 will be administered subcutaneously
DRUG	Pomalidomide	Pomalidomide will be self-administered as a single dose orally
DRUG	Dexamethasone	Dexamethasone will be administered orally or intravenously
DRUG	QL2109 or Daratumumab	QL2109 or Daratumumab will be administered subcutaneously.
DRUG	Bortezomib	Bortezomib will be administered subcutaneously
DRUG	Lenalidomide	Lenalidomide will be self-administered as a single dose orally

Timeline

• Start date: 2025-09-12
• Primary completion: 2027-11-01
• Completion: 2028-07-01
• First posted: 2025-06-12
• Last updated: 2025-09-22

Locations

1 site across 1 country: China